Tags

Type your tag names separated by a space and hit enter

Management of Refractory Pediatric Sarcoma: Current Challenges and Future Prospects.
Onco Targets Ther. 2020; 13:5093-5112.OT

Abstract

Paediatric sarcomas are a heterogeneous group of disorders constituting bone sarcoma and various soft tissue sarcomas. Almost one-third of these presents with metastasis at baseline and another one-third recur after initial curative treatment. There is a huge unmet need in this cohort in terms of curative options and/or prolongation of survival. In this review, we have discussed the current treatment options, challenges and future strategies of managing relapsed/refractory paediatric sarcomas. Upfront risk-adapted treatment with multidisciplinary management remains the main strategy to prevent future recurrence or relapse of the disease. In the case of limited local and/or systemic relapse or late relapse, initial multimodality management can be administered. In treatment-refractory cases or where cure is not feasible, the treatment options are limited to novel therapeutics, immunotherapeutic approach, targeted therapies, and metronomic therapies. A better understanding of disease biology, mechanism of treatment refractoriness, identifications of driver mutation, the discovery of novel targeted therapies, cellular vaccine and adapted therapies should be explored in relapsed/refractory cases. Close national and international collaboration for translation research is needed to fulfil the unmet need.

Authors+Show Affiliations

Department of Medical Oncology, AIIMS, New Delhi, India.Department of Medical Oncology, AIIMS, New Delhi, India.Department of Medical Oncology, Tata Medical Center, Kolkata, India.Department of Medical Oncology, Tata Medical Center, Kolkata, India.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32606731

Citation

Pushpam, Deepam, et al. "Management of Refractory Pediatric Sarcoma: Current Challenges and Future Prospects." OncoTargets and Therapy, vol. 13, 2020, pp. 5093-5112.
Pushpam D, Garg V, Ganguly S, et al. Management of Refractory Pediatric Sarcoma: Current Challenges and Future Prospects. Onco Targets Ther. 2020;13:5093-5112.
Pushpam, D., Garg, V., Ganguly, S., & Biswas, B. (2020). Management of Refractory Pediatric Sarcoma: Current Challenges and Future Prospects. OncoTargets and Therapy, 13, 5093-5112. https://doi.org/10.2147/OTT.S193363
Pushpam D, et al. Management of Refractory Pediatric Sarcoma: Current Challenges and Future Prospects. Onco Targets Ther. 2020;13:5093-5112. PubMed PMID: 32606731.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Management of Refractory Pediatric Sarcoma: Current Challenges and Future Prospects. AU - Pushpam,Deepam, AU - Garg,Vikas, AU - Ganguly,Sandip, AU - Biswas,Bivas, Y1 - 2020/06/08/ PY - 2020/02/04/received PY - 2020/05/12/accepted PY - 2020/7/2/entrez PY - 2020/7/2/pubmed PY - 2020/7/2/medline KW - disease biology KW - immunotherapy KW - osteosarcoma KW - paediatric sarcoma KW - relapsed sarcoma KW - targeted therapy SP - 5093 EP - 5112 JF - OncoTargets and therapy JO - Onco Targets Ther VL - 13 N2 - Paediatric sarcomas are a heterogeneous group of disorders constituting bone sarcoma and various soft tissue sarcomas. Almost one-third of these presents with metastasis at baseline and another one-third recur after initial curative treatment. There is a huge unmet need in this cohort in terms of curative options and/or prolongation of survival. In this review, we have discussed the current treatment options, challenges and future strategies of managing relapsed/refractory paediatric sarcomas. Upfront risk-adapted treatment with multidisciplinary management remains the main strategy to prevent future recurrence or relapse of the disease. In the case of limited local and/or systemic relapse or late relapse, initial multimodality management can be administered. In treatment-refractory cases or where cure is not feasible, the treatment options are limited to novel therapeutics, immunotherapeutic approach, targeted therapies, and metronomic therapies. A better understanding of disease biology, mechanism of treatment refractoriness, identifications of driver mutation, the discovery of novel targeted therapies, cellular vaccine and adapted therapies should be explored in relapsed/refractory cases. Close national and international collaboration for translation research is needed to fulfil the unmet need. SN - 1178-6930 UR - https://www.unboundmedicine.com/medline/citation/32606731/Management_of_Refractory_Pediatric_Sarcoma:_Current_Challenges_and_Future_Prospects L2 - https://dx.doi.org/10.2147/OTT.S193363 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.